Clear Harbor Asset Management’s Eiger BioPharmaceuticals, Inc. EIGR Stock Holding History

Clear Harbor Asset Management’s Portfolio EIGR Stock Details EIGR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-683	Closed	-$129K	–	404
2022 Q2	$129K	Buy	+683	New	+$138K	0.02%	349

Other funds holding EIGR

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

IVM

InterWest Venture Management San Francisco, California $20.6M AUM 48.5% 1-Year Est. Return

Clear Harbor Asset Management's EIGR Position: Q3 2022 in Review

Clear Harbor Asset Management sold out of Eiger BioPharmaceuticals, Inc. (EIGR) in Q3 2022, closing a stake of 683 shares — an estimated $129K sold.

Clear Harbor Asset Management first reported a position in EIGR in Q2 2022 and held it in 1 quarter. The position peaked at $129K in Q2 2022. 92 funds tracked by Wall St. Rank hold EIGR as of Q3 2022.

Clear Harbor Asset Management reported no remaining Eiger BioPharmaceuticals, Inc. position as of Q3 2022 after selling out during the quarter.
Clear Harbor Asset Management sold 683 Eiger BioPharmaceuticals, Inc. shares in Q3 2022, an estimated $129K.
Clear Harbor Asset Management first reported a position in Eiger BioPharmaceuticals, Inc. in Q2 2022 and held it in 1 quarter.
Clear Harbor Asset Management's Eiger BioPharmaceuticals, Inc. position peaked at $129K in Q2 2022.
92 funds tracked by Wall St. Rank held Eiger BioPharmaceuticals, Inc. as of Q3 2022.

Based on Clear Harbor Asset Management's 13F filing for Q3 2022, filed 25 Oct 2022.